The Investigation of Effects of Quercetin and Its Combination with Cisplatin on Malignant Mesothelioma Cells In Vitro by Demiroglu-Zergeroglu, A. et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2010, Article ID 851589, 7 pages
doi:10.1155/2010/851589
Research Article
The Investigation of Effectsof Quercetinand Its Combination
withCisplatinonMalignant MesotheliomaCellsIn Vitro
A.Demiroglu-Zergeroglu,1 B. Basara-Cigerim,1 E.Kilic,2 andG.Yanikkaya-Demirel3
1Department of Biology, Faculty of Science, Gebze Institute of Technology, Gebze 41400, Kocaeli, Turkey
2Department of Clinical Biochemistry, Erciyes University, 38039 Kayseri, Turkey
3Istanbul Centro Laboratories, 34400 ˙ Istanbul, Turkey
Correspondence should be addressed to A. Demiroglu-Zergeroglu, ademiroglu@gyte.edu.tr
Received 28 December 2009; Revised 21 March 2010; Accepted 25 March 2010
Academic Editor: Michael Kalafatis
Copyright © 2010 A. Demiroglu-Zergeroglu et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Malignant Mesothelioma (MM) is an aggressive and lethal tumour of the serosal surfaces with poor prognosis. In this study, we
have investigated the antiproliferative eﬀect of Quercetin (QU) and its combination with Cisplatin (CIS) on SPC212 and SPC111
cell lines. Our experiments showed that QU signiﬁcantly reduced the proliferation of cell lines, altered the cell cycle distribution,
and increased the level of Caspase 9 (C9) and Caspase 3 (C3) in concentration and time-dependent manner. Additionally, the
combination of QU + CIS was found more eﬀective when compared with individual treatment of agents.
1.Introduction
MM is a deadly and diﬃcult disease to treat [1]. Chemother-
apeutic agents including Gemcitabine, Imatinib/Gleevec,
Geﬁtinib/Iressa, Bevacizumab/Avastin, Pemeterexed + CIS,
and Gemcitabine + CIS are currently used to treat patients
of MM [2–6]. However, treatments are not always successful.
The bioactivity of ﬂavonoids has been shown in many
biological mechanisms related to cancer [7, 8]. QU is known
to possess anticarcinogenic eﬀects, which interfere with the
pathways of cancer. QU has been previously reported to have
antiproliferative eﬀects on numerous cancers cells including
leukemia [9], breast carcinoma [10], colon adenocarcinoma
[11], prostate [12], and endometrial cancer [13]. It has also
been reported that QU blocks colon, gastric cancer, and
human leukemic T cells at G1/S phase of cell cycle [14]a n d
arrests nononcogenic ﬁbroblast and laryngeal, breast, and
human acute leukaemia cancer cells at G2/M phase [15–18].
In addition QU induces apoptosis in leukaemia [19],
breast [20], ovarian [21], lung [22], oral [23], and colon
cancer, [24] and melanoma [25]. CIS is widely used in
the treatment of several cancers including head and neck,
testicular ovarian, cervical, lung, colorectal, and relapsed
lymphoma [26]. CIS and the other platinum drugs are
conventionally employed by chemotherapeutic protocols
against MM. However, mesothelial cells were found to be
intrinsically resistant to CIS [27]. Although the anticar-
cinogenic eﬀects of CIS and QU have been investigated
separately, there is limited data, in the literature examining
the combined eﬀe c t s .C I S+Q Ui nc o m b i n a t i o na p p e a rt o
have a pro-apoptotic eﬀect in HeLa cells [28]. Additionally,
QU has been shown to enhance the antiproliferative eﬀect of
CIS in leukaemia (HL-60 and L1210) and human laryngeal
Hep2 cells [29].
The biological functions of QU combined with CIS on
MM cells have not been examined before. In this paper, we
have investigated the dose- and time-dependent antiprolifer-
ative and apoptotic eﬀects of QU and its combination with
CIS on MM cell lines.
2.MaterialsandMethods
2.1. Cell Lines. MM cells were obtained from The Institute of
Histology and General Embryology, University of Fribourg,
Switzerland. SPC111 cell lines were derived from pleural
eﬀusion with mixed histology of male patient and SPC212
cells originate from tumour with mixed histology of female2 Journal of Biomedicine and Biotechnology
patient. All the cells were maintained in RPMI 1640 medium
(Invitrogen-Gibco) supplemented with 10% FBS, 9.2%
NaHCO3 (Sigma-Aldrich), and 1% penicillin/streptomycin
(Invitrogen-Gibco) and incubated at 37◦C in a humidiﬁed
atmosphere containing 5% CO2 in the air.
2.2. Drugs and Reagents. QU (3, 3 ,4  ,5  ,7  -pentahy-
droxy ﬂavone) and CIS (Cis-diamminedichloroplatinum
Pt (NH3)2Cl2) were purchased from Sigma-Aldrich. Both
drugs were dissolved in dimethyl sulfoxide (DMSO) (cell
culture tested; Sigma-Aldrich) as 1000-fold concentrated
stock solutions and stored at −20◦C .I no r d e rt oa v o i d
photoisomerization, all procedures involving drugs were
prepared under subdued lighting.
2.3. Assay for Proliferation. One thousand cells per well were
seeded in a 96-well plate for 24 hours. Then they were
incubatedwithdiﬀerentconcentrationsofQU(5,10,50,and
100μM), CIS (1, 5, and 10μg/mL), and CIS + QU (5μg/mL
+5 0μMa n d1 0μg/mL + 50μM) for 0–96 hours. Following
incubations, a cell titer 96 Aqueous One Solution Cell
Proliferation Assay Kit (Promega Madison, W1 USA) was
used to measure cell proliferation rate. Two wells of medium
without cells were used to give background readings. To each
well 20μl of MTS compound was added and the plates were
incubated 2 hours before reading the absorbance at 490nm
with an Elisa reader (Bio-tek instruments.inc).
2.4. Assay for Cell Cycle Distribution. The cells (1 × 106)
were plated into 50mm diameter Petri dishes and incubated
overnight then treated with QU, CIS, and CIS + QU combi-
nations for 24 and 48 hours. At the end of each incubation
period, cells were harvested using Trypsin-EDTA (Sigma-
Aldrich) washed with ice-cold 1X PBS and ﬁxed in cold 70%
ethanol. After ﬁxation, cells were washed twice with PBS and
incubated in dark for 30 minutes with a staining solution
containing 0.1% Triton X-100/PBS (Sigma-Aldrich) with
1mg/mL of RNase A (Sigma-Aldrich) and PI (20μg/mL)
(Sigma-Aldrich) at room temperature. Fluorescence emitted
from the PI-DNA complex was quantiﬁed after excitation of
the ﬂuorescent dye by FACScan ﬂow cytometry (Beckman
Coulter Epics XL-MCL).
2.5. Assay for Cell Apoptosis. Both cell lines were initially
culturedinPetridishesfor24hours.QU(50μM),CIS(5and
10μg/mL), and CIS + QU (5μg/mL + 50μMa n d1 0μg/mL
+5 0μM) were added for further 48 hours. 5 × 106 cells were
washed with ice-cold PBS and lysed with caspase cell lysis
buﬀers (Biovision, USA). The lysates were then centrifuged,
and the amount of protein was measured by Bicinchoninic
acid (BCA) assay at 24 and 48 hour intervals. Samples
containing 100μg of total protein were assayed with LEHD-
pNA as a caspase-9-speciﬁc substrate (Biovision, USA) for
C9 activity and with DEVD-pNA as a caspase-3-speciﬁc
substrate (Biovision, USA) for C3 activity. The absorbance
was measured at 405nm in a microplate reader.
2.6.StatisticalAnalysis. Resultswereexpressedasmean±s.d.
of three-ﬁve independent experiments and each experiment
included duplicate sets. Data was statistically evaluated by
one-way ANOVA followed by Dunnett’s test. The level of
signiﬁcance was chosen as ∗P <. 05, ∗∗P <. 01 between
control groups and multiple doses, #P <. 05 between QU +
CIS treatment and CIS alone, and ##P <. 05 between QU
+ CIS treatment and QU alone. Flow cytometric histograms
were generated in linear mode and then analyzed using
multicycle DNA software.
3. Results
3.1. Eﬀects of QU and QU + CIS on Cell Proliferation.
To examine the eﬀects of QU, CIS, and CIS + QU on
SPC212 and SPC111 cells, exponentially growing cells were
treated by QU (0–100μM), CIS (1–10μg/mL), and CIS
+Q U( 5 μg/mL + 50μMa n d1 0 μg/mL + 50μM) for
96 hours. The growth inhibition of SPC212 cells was
observed at concentrations of QU ≥ 10μMa t7 2h o u r s
(Figure 1(a))andCIS ≥5μg/mL(datanotshown).However,
QU reduced the proliferation of SPC111 cells at concen-
trations ≥50μMa t7 2h o u r s( Figure 1(b)). Thus, to prove
the ability of QU to enhance anti-proliferative activity of
CIS, the optimal dose of QU (50μM) was used for 96
hours. As shown in Figure 2(a),5 μg / m L C I S+5 0 μMQU
and 10μg/mlCIS + 50μMQU applications signiﬁcantly
decreased the proliferation of SPC212 cells when compared
with control and the individual agents. The proliferation
of SPC111 was also inhibited at same concentrations
when compared with control cells, but combined eﬀect
was not signiﬁcantly diﬀerent from the eﬀects observed
in individual treatments on SPC111 cells for 96 hours
(Figure 2(b)). In summary, agents inhibited proliferation of
SPC212 and SPC111 cells independently or in combination
at dose- and time-dependent manner, and combination
of CIS + QU resulted in an enhanced antiproliferative
activity.
3.2. Eﬀect of Treatments on Cell Cycle Distribution. To
investigate eﬀect of QU (50μM), CIS (5 and 10μg/mL),
and CIS + QU (5μg/mL + 50μMa n d1 0μg/mL + 50μM)
on the cell cycle progression of MM cells, we performed
a ﬂow cytometric analysis by using PI staining. As shown
in Figure 3(b),5 0μMd o s eo fQ Uc a u s e da c c u m u l a t i o no f
SPC212 cells at S phase. However no alteration was observed
at the cell cycle proﬁle of SPC111 cells when compared with
control cells at 48 hours (Figures 3(c) and 3(d)). Following
5μg/mL CIS treatments, both cell lines were arrested in S
phase for 24 hours (Figures 3(a) and 3(c)), then cells were
passed through to G2/M phase in the next 24-hour period
(Figures 3(b) and 3(d)). However, when 5μg/mL CIS was
used in combination with 50μM Q Ub o t hc e l ll i n e sw e r e
arrested and kept in S phase for 48 hours. The percentage of
cellsreachedupto86%,7%and99%inSPC212andSPC111
cells, respectively at 48 hours (Figures 3(b) and 3(d)). This
result might suggest that the prolongation of S phase was
due to enhanced antiproliferative eﬀect. On the other hand,
when CIS dose was increased to 10μg/mL and applied with
50μMQU, the combination eﬀect was not observed to beJournal of Biomedicine and Biotechnology 3
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Figure 1: SPC212 (a) and SPC111 (b) cells were cultured and treated with 5μMQU ,10μMQU ,50μM QU, and 100μMQU for 0–96 hours.
Applications of QU > 10μMa n dQ U≥ 50μM caused reduction of cell numbers in SPC212 and SPC111 cells at 72 hours, respectively. Data
was statistically evaluated between control group and multiple dose groups of QU, with the level of signiﬁcance chosen as
∗P <. 05 and
∗∗P <. 01.
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Figure 2: SPC212 (a) and SPC111 (b) cells were untreated and treated with 5μg/mlCIS, 10μg/mLCIS, 50μMQU and 5μg/mLCIS +
50μMQU , and 10μg/mL CIS + 50μMQU for 0–96 hours. Cell proliferation decrease imposed by QU, CIS, and QU + CIS was time
dependent. Combination treatments were found more eﬀective than individual treatments in SPC212 cells in 96 hours (a). Additionally,
both individual and combination applications reduced cell proliferation in SPC111 cells when compared with untreated cells in 96 hours
(b); however no signiﬁcant diﬀerences were observed on the reduction of cell proliferation when compared with combined and individual
treatments in 96 hours. Data was statistically evaluated between control group, single dose groups, and combination dose groups, with the
level of signiﬁcance chosen as
∗P ≤ .05;
∗∗P ≤ .01, and #P <. 05 between QU + CIS treatment and CIS alone.
diﬀerent from individual treatments in SPC111 cells (Figures
3(a), 3(b), 3(c),a n d3(d)).
3.3. Eﬀect of Treatments on C3 and C9 Activity. Both
cell lines were treated with 5μg/mLCIS + 50μMQU and
10μg/mLCIS + 50μMQU in combination as well as
individually. Caspase activities were measured after drug
treatments at 24 and 48 hours. Increased C9 activity was
observed in SPC212 compared to the control cells and
the cells treated with single doses of 5, 10μg/mL CIS,
and 50μM QU at 48h. Additionally 5μg/mLCIS + 50μM
QU and 10μMC I S+5 0 μM QU signiﬁcantly raised C9
activation when compared with individual treatments at
48 hours ( ###P <. 05) (Figure 4(a)). Increased C3 acti-
vation was also detected in SPC212 cell lines at the same
concentration of drugs individually and in combination
for 48 hours (Figure 4(b)). Interestingly, 10μg/mLCIS +
50μM QU applications activated both caspases at 24 hours
(Figures 4(a) and 4(b)). On the contrary, SPC111 cell
lines showed diﬀerent proﬁle on caspase activation. No C9
activation was observed with individual doses of agents but
only 10μg/mLCIS + 50μMQU applications activated C9
(Figure 4(c)). As shown in Figure 4(d) neither single nor
combined treatments activated C3 in SPC111 cells.
4. Discussion
In this paper, we have investigated the eﬀects of the QU
moleculealoneandincombinationwithachemotherapeutic
agent, CIS, on two MM cell lines. Antiproliferative action of4 Journal of Biomedicine and Biotechnology
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Figure 3: SPC212 cells ((a) and (b)) and SPC111 cells ((c) and (d)) were untreated, treated with 5μg/mL CIS, 10μg/mL CIS, 50μMQU ,
and combination of both at 24 hours ((a) and (c)) and 48 hours ((b) and (d)). Accumulation of cells in S phase was detected in SPC212 but
not in SPC111 cells following QU treatments for 48 hours ((b) and (d)). However, individual CIS applications resulted in accumulation of
both cells in S phase at the ﬁrst 24 hours period ((a) and (c)), and cells were arrested at G2/M phase in the following 24 hours ((b) and (d)).
Distribution of cell cycle was altered in both cells with 5μg/mLCIS + 50μMQU treatment compared with untreated cells and cells were
treated with individual agents. The percentage of S phase arrest was observed as 86.7% in SPC212 and 99% in SPC111 cells, at 48 hours ((b)
and (d)). On the other hand, cells treated with 10μg/mLCIS + 50μMQU showed a similar proﬁle to that of individual 10μg/mLCIS dose
applications in SPC111 cells ((c) and (d)).
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Figure 4: SPC212 ((a) and (b)) and SPC111 cells ((c) and (d)) were treated with 5μg/mLCIS, 10μg/mLCIS, 50μMQU ,5μg/mLCIS +
50μMQU ,and10μg/mL CIS + 50μMQU for 48 hours. C9 ((a) and (c)) and C3 ((b) and (d)) activities were measured as indicated in
Section 2.5 compared to control and single agent treatments. 10μg/mLCIS + 50μMQU combinations activated C9 in both cell lines for 48
hours ((a) and (c)). C9 and C3 activities were increased in SPC212 cells following 10μg/mLCIS + 50μMQUat24hourswhencomparedto
the control cells and the cells treated with individual doses of QU and CIS ((a) and (b)). Additionally, 5μg/mLCIS + 50μMQU combination
treatments of SPC212 cells were found eﬀective to activate C9 and C3 molecules at 48 hours ((a) and (b)). In addition C9 was activated with
10μg/mLCIS + 50μMQU applications on SPC111 cells. However, there was no C3 activity detected in SPC111 cells for 48 hours (d). Data
was statistically evaluated between control group, single dose groups and combination dose groups, with the level of signiﬁcance chosen as
∗P ≤ .05,
∗∗P ≤ .01, #P <. 05 between QU + CIS treatment and CIS alone, and ##P <. 05 between QU + CIS treatment and QU alone.Journal of Biomedicine and Biotechnology 5
QU on MM cells was observed in dose- and time-dependent
manner.
QU inhibited cell proliferation of SPC212 and SPC111
cells at concentrations of QU > 10μMa n dQ U≥ 50μM,
respectively (Figures 1(a) and 1(b)). However, we have
observedabiphasiceﬀectofQU<50μM.Interestingly,doses
less then 50μM of QU treatment increased cell proliferation
of SPC111 cells (Figure 1(b)). The dual eﬀect of QU on the
cell proliferations has been previously described in human
oral cancer cells, SCC-25 [30], colon carcinoma (HCT-
116 and HT-29), and mammary adenocarcinoma cell lines
(MCF-7) [31]. Moreover, the protective eﬀect at low con-
centrations and the cytotoxic eﬀects at high concentrations
(QU ≥ 50μM) were indicated in rat cells [32]. These results
suggest that related to the utilised dose QU works diﬀerently
in the same cells. Furthermore, QU actions were also found
to be cell selective. As indicated in [33], QU inhibited growth
of aggressive PC-3 cells and DU145 prostate cancer cells
but was not eﬀective on poorly aggressive LNCaP prostate
cancer and normal BG-9 ﬁbroblasts. Our results indicate
that QU applications caused reduction of cell numbers in
both SPC212 and SPC111 cells. Additionally, SPC212 cells
were aﬀected by QU at lower doses compared to that of
SPC111 suggesting the former cells were more sensitive to
QU treatments.
Mesothelial cells were found to be intrinsically resistant
to CIS [27], and CIS + QU in combination appear to have
enhanced antiproliferative eﬀect in leukaemia and human
laryngeal cells [29]. Therefore, combination experiments
were performed to investigate whether addition of QU to
CIS enhanced anti-proliferative activity on MM cells. Our
experiments indicate that combined QU + CIS applications
were much more eﬀective to inhibit cell proliferation than
using agents individually (Figures 2(a) and 2(b)).
The eﬀect of QU on the cell cycle distributions was
pointed out in various cells including G1/S transition
in gastric cancer and human leukemic T cells [14]a n d
G2/M block in nononcogenic ﬁbroblast, laryngeal, breast,
and human acute leukaemia cancer cell lines [18–20]. In
our experiments, applications of 50μMQU resulted in S
phase arrest in SPC212 cells (Figures 3(a) and 3(d))b u t
not in SPC111 cells (Figures 3(c) and 3(d)). In addition,
5μg/mLCIS + 50μM Q Ut r e a t m e n t sa c c u m u l a t e db o t h
cells in S phase and there were no transition to G2/M
phase between 24 and 48 hours (Figures 3(a), 3(b), 3(c),
and 3(d)). These results might suggest the existence of
enhanced antiproliferative eﬀect due to CIS + QU working
in combination. However, when CIS dose was increased to
10μg/mLandappliedwith50μMQU,thecombinationeﬀect
was not diﬀerent from individual treatments in SPC111 cells
(Figures 3(c) and 3(d)).
Several groups demonstrated that treatment with QU
causes apoptosis [19–25, 34, 35]. QU leads to activation of
C3 in HPB-ALL [36], HT-29 colon cancer cells [37], and
pancreatic cells [34], C3 and C9 activation in HL-60 [38],
and C3, C7, and C9 activation in A549 lung cancer cells
[22]. In our experiments, C9 and C3 activation in SPC212
(Figures 4(a) and 4(b)) and C9 activation in SPC111 cells
were observed (Figure 4(c)), indicating that apoptosis was
induced by QU. The eﬀe c to fQ Uw a sf o u n dt ob et i m ea n d
dose dependent.
The enhanced eﬀe c to fQ Uo nC I Sw a sr e p o r t e di n
human laryngeal Hep2 cells. 2, 5μg/mLCIS + 40μMQU
induced apoptosis and increased C9 and C8 activity [39]. In
addition, 10μg/mLCIS + 15μg/mLQU enhanced the pro-
apoptotic eﬀect of HeLa cells through strong activation of
C3 [28]. It is also reported that QU inhibits growth of
several cancer cell lines where anti-proliferative activity was
mediated by Type II Estrogen-Binding Sides (Type II EBS)
[40, 41]. Furthermore, it is suggested that QU may synergize
with CIS by interaction with these binding sites [41, 42].
We observed that QU alone and in combination with CIS
activated C9 and C3 in SPC212 cells. Activation level of
caspases was signiﬁcantly increased by combine treatments
when compared with individual agents (Figures 4(a) and
4(b)).
Although similar experiments were performed in diﬀer-
ent cancer cells, to our best knowledge, this is the ﬁrst report
investigating anti-proliferative activity of QU and QU + CIS
partnership on MM cells in vitro. QU alone and together
with CIS have an anti-proliferative potential on MM cells by
reducingcellproliferationandalteringthecellcycleproﬁleof
both cells. In addition, C9 and C3 activations were observed,
indicating that apoptosis induced by agents alone and in
combination.
The interaction between QU and CIS might provide
an interesting approach to combination therapy of MM.
This may allow the use of lower concentration of the
chemotherapeutic drug CIS and will also have the beneﬁt of
increased eﬃciency and reduction in side eﬀects and drug
resistance.
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